Treatment Outcomes of Active Multiple Myeloma in Two Egyptian Oncology Centers
/ 0
- Details
- Category: Vol. 82, June 2014
- Hits: 828
Treatment Outcomes of Active Multiple Myeloma in Two Egyptian Oncology Centers, NASR M.A. ALLAHLOUBI, ALFRED E. NAMOUR, YASSER A. SALLAM, MOSAAD EL GAMMAL, FOUAD M. ABU-TALEB and YASSER A. MOHAMMED
Abstract
Introduction: Multiple myeloma (MM) is a malignant neoplasm of plasma cells accounting for approximately 10% of all hematologic cancers.
Aim: To report the experience of the Egyptian National Cancer Institute (ENCI) and Zagazig University Hospital in managing multiple myeloma.
Methods: This retrospective study involved 53 patients diagnosed with active multiple myeloma between 2002-2007 in the Medical Oncology Department at the National Cancer Institute, Cairo University and Internal Medicine Department, Faculty of Medicine, Zagazig University Hospital.
Results: The median age of patientås is 57 years. The majority of patients are below 60yrs (69.8%), and there is male predominance (71.7%). Baseline investigations revealed anemia (Hb£10gm/dl) in 49.1%, impaired renal function (serum Creatinine >1.4mg/dl) in 17%, hypercalcemia (serum calcium >1 1mg) in 28.3%, and ISS stage III (B2-microglobulin >!5.5mg) in 34%. The induction treatment protocols used were VAD in 73.6%, and melphlan & steroids (MP) in 9.4%. PFS of multiple myeloma patient at 6 months and one year OS of patients of the study and correlation to different prognostic factors revealed significant correlation to age (p=0.003), serum calcium (p=0.009), and serum Creatinine (p=0.006). V.A.D had significantly better outcome MP protocol or best supportive care (p=0.001).
Conclusions: Multiple myeloma is a sensitive incurable disease with traditional treatment protocols, with age, baseline creatinine and serum calcium among the major prognostic variables.